BGB 3111

Drug Profile

BGB 3111

Alternative Names: BGB3111

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BeiGene
  • Developer BeiGene; Peter MacCallum Cancer Centre
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia; Mantle-cell lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Phase I B cell lymphoma

Most Recent Events

  • 02 Nov 2017 Phase-III clinical trials in Chronic lymphocytic leukaemia (First-line therapy) in USA (PO) (NCT03336333)
  • 01 Nov 2017 Phase-II clinical trials in Follicular lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03332017)
  • 30 Sep 2017 BeiGene completes enrolment in its phase II trial for Mantle cell lymphoma in China (NCT03206970)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top